This treatment rendered the cells more BRAF inhibition resistant compared to the negative control by approximately 2 fold (n = 2 IC50: negative control = 0.5198 μM [SEM = 0.0695 μM], sgEGFR = 1.146 μM [SEM = 0.146 μM], sgENSG182165_5 = 1.778 μM [SEM = 1.0274 μM], sgENSG224397_1 = 1.100 μM [SEM = 0.3836], sgENSG226527_6 = 0.8242 μM [SEM = 0.1313 μM], sgXLOC_067371_5 = 0.94 μM [SEM = 0.3012 μM]) supporting the foundation to identify lncRNAs involved in melanoma BRAFi resistance. Here, BRAF is linked to melanoma.